Item 5.02 Regulation FD Disclosure.

Effective September 23, 2022, Blueprint Medicines Corporation (the "Company") entered into employment agreement amendments with its chief executive officer (principal executive officer), chief financial officer (principal financial officer), other named executive officers and other officers of the Company (collectively, the "executives"), which have been Attorney Client Privileged & Confidential approved by the Compensation Committee of the Board of Directors of the Company (the "Compensation Committee").

The amendments reflect each executive's current annual target incentive compensation as approved in the first quarter of this year by the Compensation Committee, as well as by stockholders, via a non-binding advisory vote, at the Company's Annual Meeting of Stockholders held on June 21st of this year. The amendments also align the way the executives' annual target incentive compensation is described to be consistent with the way annual base salary is described throughout the employment agreements. For example, the description of annual base salary in the employment agreements has always included the statement that it may be adjusted from time to time by the Compensation Committee or the Board of Directors, which alleviates the need to amend the employment agreement each time a salary adjustment is made. These current amendments provide that same flexibility for target incentive compensation, so that any potential future adjustments approved by the Compensation Committee will not require further employment agreement amendments.

The foregoing description of the amendments are qualified in their entirety by reference to the complete text of each such agreement, copies of which are attached as Exhibits 10.1 to 10.11 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.



Exhibit No.  Description
  10.1         First Amendment to Amended and Restated Employment Agreement,
             dated September 23, 2022, by and between the Registrant and Kathryn
             Haviland
  10.2         Third Amendment to Employment Agreement, dated September 23,
             2022, by and between the Registrant and Michael Landsittel
  10.3         First Amendment to Amended and Restated Employment Agreement,
             dated September 23, 2022, by and between the Registrant and
             Christina Rossi
  10.4         Second Amendment to Employment Agreement, dated September 23,
             2022, by and between the Registrant and Fouad Namouni
  10.5         Second Amendment to Employment Agreement, dated September 23,
             2022, by and between the Registrant and Tracey L. McCain
  10.6         Second Amendment to Employment Agreement, dated September 23,
             2022, by and between the Registrant and Lemuel Becker Hewes
  10.7         Second Amendment to Employment Agreement, dated September 23,
             2022, by and between the Registrant and Christopher Murray


  10.8         Second Amendment to Employment Agreement, dated September 23,
             2022, by and between the Registrant and Percy H. Carter
  10.9         Third Amendment to Employment Agreement, dated September 23,
             2022, by and between the Registrant and Debra Durso-Bumpus
  10.10        Second Amendment to Employment Agreement, dated September 23,
             2022, by and between the Registrant and Ariel Hurley
  10.11        First Amendment to Amended and Restated Employment Agreement,
             dated September 23, 2022, by and between the Registrant and Philina
             Lee
104          Cover Page Interactive Data File (embedded within the Inline XBRL
             document and incorporated as Exhibit 101)

© Edgar Online, source Glimpses